During EuroTIDES 2017 discuss oligonucleotide development challenges with our experts, November 7- 10, 2017, Vienna
Accelerating oligonucleotide products from early discovery to late-stage development & commercialization is not without challenges.
With a growing global development pipeline of oligonucleotide therapeutics to treat a variety of disease targets, overcoming the challenges of innovation, and regulatory authorization, production and the inherent complexity of these products is critical to success.
During EuroTIDES 2017, the Intertek team will be available to discuss your outsourcing requirements to address the critical stages of oligo, chemistry, manufacturing and controls (CMC), marketing authorization and GMP manufacturing. Our experts in oligonucleotide analysis and bioanalysis, will be on hand to discuss our regulatory-driven, phase-appropriate characterization and biophysical analysis in support of CMC programs which include confirmation of the oligonucleotide identity, assay, and identification / determination of impurities and degradation products.
EuroTIDES Conference Presentation
Thursday 9 November 2017, 14:00, TRACK: CMC and Analytical Methods
Title: Analytical Method Development and Validation for Oligonucleotide Therapeutics
Speaker: Ashleigh Wake, Director of Biological Services
REQUEST a copy of our presentation
Our specialists in GMP and CMC laboratory services, pharmaceutical analysis, quality control analysis, elemental impurities, extractables and leachables, stability programs, inhalation drug development, method development and method validation will be available to review your challenges and discuss and how our unrivalled expertise can help you to accelerate the development timelines.
Learn more about EuroTIDES 2017
EuroTIDES 2017 is an opportunity to discuss best practices and learn more about important industry developments across the entire spectrum of oligonucleotide therapeutics. During the conference the topics of R&D strategies, oligonucleotide manufacturing and scale up, nonclinical, preclinical and clinical updates for oligonucleotides, mRNA therapeutics, CMC and analytical method development strategies for oligonucleotides will be discussed.
Need help or have a question?